Articles

Phase III CheckMate -77T trial data show statistically significant improvements in event-free survival with Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo in the treatment of resectable stage IIA to IIIB non-small cell lung cancer.  

Regulatory Submissions Filed for Opdivo Regimen in Resectable Non-Small Cell Lung Cancer 

DB Schenker, JAS, Medista, MSC Air Cargo, OnAsset Intelligence, and xpd global round out the latest additions. 

Pharma.Aero Welcomes Six New Members to Its Roster

Cohort study dives into whether low income subsidy losses are associated with disability status, age, and race and ethnicity. 

Exploring the Frequency That Beneficiaries Encounter Subsidy Losses Attributed to Medicare Part D’s Low-Income Subsidy Program

BioNTech SE and Duality Biologics Co's BNT325/DB-1305 is a next-generation antibody-drug conjugate that targets the TROP2 protein, which is overexpressed across various tumor types. 

Novel ADC in Trials for Ovarian, Fallopian Tube, Primary Peritoneal Cancers Gets FDA Fast Track Designation

Arexvy was the first FDA-approved respiratory syncytial virus (RSV) vaccine to prevent lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

FDA to Review Application to Expand Indication of RSV Vaccine Arexvy to Adults Aged 50-59 Years

The air cargo market numbers close out the year slightly below 2022’s performance.

December Air Freight Demand Rallies to End the Year

The February issue is centered around third-party logistics providers, including  new dynamics and future trends that affect this key supply chain link.

The Value of 3PLs 

A cohort study investigates the impact of Senate Bill 2994A and answers the question: does the repeal of school-entry nonmedical vaccination exemptions result in a rise in school vaccinations?

The Correlation Between a New York State Law Repeal and Vaccine Coverage in Schools

UV1 is an off-the-shelf vaccine that has demonstrated a survival benefit in combination with ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with unresectable malignant pleural mesothelioma.

FDA Grants Fast Track Designation to Cancer Vaccine for Malignant Pleural Mesothelioma  

The acquisition expands Merck’s portfolio in the veterinary pharma space. 

News